人工智能辅助诊断领域的先驱 鹰瞳科技 推动医疗创新

, Aicon had facilitated the early detection of chronic diseases such as hypertension, Alzheimer’s disease, stroke, and diabetes in over five million people utilizing Eagle Eye Technology’s retinal AI evaluation system.

“AI Fundus Imaging enables the diagnosis of over ten types of eye diseases with accuracy comparable to expert-level ophthalmologists,” stated Professor Wei Wenbin, Vice President of Capital Medical University Affiliated Beijing Tongren Hospital. Tongren Hospital’s data further substantiated these findings, revealing that Eagle Eye Technology’s AI system achieved a far higher diagnostic efficiency for ten eye diseases compared to human physicians, requiring less tas cardiovascular disease and Alzheimer’s disease solely through fundus scans?

“The eyes are intricately connected to nearly all systems and organs in our bodies, and therefore, their health status is reflectedin the fundus,” explained Professor Wei Wenbin. “Chronic diseases such as diabetes, hypertension, and cardiovascular disorders manifest in alterations of the retinal vessels and nerves,” he added. This implies that analyzing retinal images can help identify underlying health issues in patients.

For instance, changes in retinal microvasculature and neural fiber layer loss are closely correlated with blood pressure. Choroidal thickness and changes in the fundus resembling leopard spots often indicate cognitive impairment, or Alzheimer’s disease. Eagle Eye Airdoc employs deep learning to analyze millions of retinal images annotated by hundreds of ophthalmologists. Leveraging this vast dataset, Eagle Eye Technology has constructed multilayer convolutional neural networks capable of image segmentation, feature extraction, quantitative analysis, and comparative analysis. These networks assess various health risks, including cardiovascular risk, stroke risk, neurological risk, and the likelihood of other chronic diseases and tumors.

The “Blue Paper” provides valuable insights into the ophthalmic health and risk distribution of individuals undergoing physical examinations in China. With the rise in age-related conditions, the nation has witnessed an increasing prevalence of eye diseases, cardiovascular disease, and other chronic conditions. Many primary healthcare facilities face resource limitations, rendering them capable only of providing post-diagnosis treatment instead of proactive health management.

To address this challenge, Eagle Eye Technology is spearheading efforts to enhance primary healthcare infrastructure. In 2023, Eagle Eye Airdoc reached a remarkable milestone by providing over ten thousand primary healthcare centers in China with access to its AI-assisted diagnostic platform. This expansion enables these clinics to offer more comprehensive health screenings, including early detection of ophthalmic and chronic diseases, to local communities.

The potential societal impact of Eagle Eye Technology’s AI fundus screening system is vast, as it could alleviate the burden of chronic diseases in China. By providing accessible and affordable health screenings, the company aims to contribute to a healthier and more equitable healthcare system for the nation.

Conclusion

The inclusion of AI-assisted diagnostics in the National Health Insurance Bureau’s guidelines marks a significant milestone in the development of AI medicine in China. Eagle Eye Technology’s pioneering efforts have demonstrated the transformative potential of AI in healthcare, particularly in the field of retinal imaging. By unlocking access to expert-level diagnostics and health risk assessments for underserved populations, Eagle Eye Technology is paving the way for a more equitable and healthier future.